by Sue Robbins | Feb 28, 2020 | Migraine
NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. Nurtec...
by Sue Robbins | Feb 27, 2020 | Migraine
Patients with psoriasis are at increased risk for migraines, according to a research letter published in the Journal of the American Academy of Dermatology. Researchers from the New York University School of Medicine examined data obtained from the 2003-2004 National...
by Sue Robbins | Feb 25, 2020 | Migraine
The United States Food and Drug Administration (US FDA) has just approved Vyepti™ for the preventive treatment of migraine. Vyepti (eptinezumab-jjmr) will be the first intravenous (IV) preventive treatment on the market for migraine disease. It will be available...
by Sue Robbins | Feb 12, 2020 | Migraine
Children and adults with obesity who lose weight may experience a reduction in migraine frequency and severity, according to findings of a new study. By searching the PubMed/Medline database, the Web of Science (formerly known as the Institute for Scientific...
by Sue Robbins | Feb 11, 2020 | Migraine
Individuals who suffer from migraine headaches appear to have a hyper-excitable visual cortex researchers at the Universities of Birmingham and Lancaster suggest. Migraines are characterised as debilitating and persistent headaches, often accompanied by an increased...
